•Oculis buys out privosegtor’s global rights from Accure•Opus Genetics completes phase 3 enrollment for OPGx-LCA5 gene therapy•FDA clears Sight Sciences' OMNI Ultra Surgical System•Harrow adds TYRVAYA's global rights to dry eye portfolio•Atopic dermatitis linked to higher retinal detachment risk•Oculis buys out privosegtor’s global rights from Accure•Opus Genetics completes phase 3 enrollment for OPGx-LCA5 gene therapy•FDA clears Sight Sciences' OMNI Ultra Surgical System•Harrow adds TYRVAYA's global rights to dry eye portfolio•Atopic dermatitis linked to higher retinal detachment risk
HEADLINES
FEATURED
Federal agency also grants priority review for the once-daily oral therapeutic, establishing a PDUFA target action date for Feb. 12, 2027.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
